As I understand it Don and RVX have no control over whether or not a 7th DSMB and/or SSRA will be conducted.

It would seem, from my perspective, that the committee would continue to check safety particularly since this is a relatively short and small sample trial so determining if there is a type of patient or length of treatment time for apabetalone when issues of toxicity could arise. I would think is critical and also in RVX's interest as evidence if the drug goes to market.

I must say that for me, in this yet another communication gap, I'm beginning to have feelings that we will not see top line findings in 2018. But that is just my concern given the RVX history of over promising and underdelivering.

I've got my fingers crossed and I hope we hear relevant information soon.

GLTA

Toinv